3,600 Shares in Jazz Pharmaceuticals PLC $JAZZ Purchased by Sanders Morris Harris LLC

Sanders Morris Harris LLC acquired a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the 3rd quarter, Holdings Channel.com reports. The fund acquired 3,600 shares of the specialty pharmaceutical company’s stock, valued at approximately $833,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JAZZ. USA Financial Formulas purchased a new position in shares of Jazz Pharmaceuticals in the 1st quarter worth $25,000. Ameritas Advisory Services LLC bought a new position in Jazz Pharmaceuticals during the 2nd quarter valued at $47,000. Westpac Banking Corp acquired a new position in shares of Jazz Pharmaceuticals in the 1st quarter worth approximately $51,000. Root Financial Partners LLC boosted its holdings in shares of Jazz Pharmaceuticals by 42.8% in the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock valued at $56,000 after buying an additional 89 shares during the period. Finally, Elevation Wealth Partners LLC grew its stake in Jazz Pharmaceuticals by 156.4% during the 3rd quarter. Elevation Wealth Partners LLC now owns 259 shares of the specialty pharmaceutical company’s stock worth $60,000 after buying an additional 158 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 1,200 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $240.94, for a total transaction of $289,128.00. Following the transaction, the executive vice president directly owned 47,671 shares of the company’s stock, valued at approximately $11,485,850.74. The trade was a 2.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Robert Iannone sold 76,921 shares of the company’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $249.70, for a total value of $19,207,173.70. Following the completion of the transaction, the executive vice president directly owned 65,686 shares in the company, valued at approximately $16,401,794.20. This represents a 53.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 100,121 shares of company stock valued at $24,855,802. 4.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of several recent analyst reports. Robert W. Baird increased their price objective on shares of Jazz Pharmaceuticals from $252.00 to $280.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. The Goldman Sachs Group started coverage on Jazz Pharmaceuticals in a research note on Thursday, September 24th. They issued a “buy” rating and a $337.00 target price on the stock. Royal Bank Of Canada lowered their price objective on Jazz Pharmaceuticals from $299.00 to $296.00 and set an “outperform” rating on the stock in a report on Thursday, October 8th. Deutsche Bank Aktiengesellschaft increased their price objective on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the company a “buy” rating in a research report on Wednesday, August 26th. Finally, Wall Street Zen lowered shares of Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $291.25.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ opened at $209.65 on Thursday. The business has a 50-day moving average price of $241.51 and a two-hundred day moving average price of $231.86. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $13.61 billion, a P/E ratio of 14.46, a P/E/G ratio of 0.21 and a beta of 0.37. Jazz Pharmaceuticals PLC has a 1-year low of $128.80 and a 1-year high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The company had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.11 billion. During the same quarter in the prior year, the company posted ($8.25) EPS. The company’s revenue for the quarter was up 15.5% compared to the same quarter last year. Equities analysts predict that Jazz Pharmaceuticals PLC will post 21.59 earnings per share for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious neurological and oncology-related conditions. Founded in 2003 and headquartered in Dublin, Ireland, the company operates internationally, with a significant commercial presence in the United States and other markets.

Jazz’s neuroscience portfolio includes Xywav and Xyrem, which contain oxybate and are used to treat narcolepsy-related symptoms; Xywav is also approved for idiopathic hypersomnia in adults.